Key Takeaways
- • Heidi Health raised $340 million in a new funding round, doubling its valuation to $900 million and establishing the Australian AI health-tech startup as a major player in clinical automation.
- • The company has now accumulated over $430 million in total funding across multiple rounds, including a $65 million Series B closed in October 2025 led by Point72 Private Investments.
- • Heidi's core technology automates clinical documentation, administrative workflows, and evidence search tasks for healthcare systems, addressing a significant pain point in physician productivity and operational efficiency.
- • Founded in 2021 by trauma surgeon Dr. Tom Kelly and Waleed Mussa, Heidi is positioned as Australia's fastest-growing AI company and is expanding adoption globally across health systems.
- • The substantial capital raise signals strong investor confidence in the commercial viability of AI-driven clinical workflow automation and reflects growing enterprise demand for healthcare technology solutions that reduce administrative burden on medical professionals.
Summary
Heidi Health, an Australian artificial intelligence startup specializing in clinical automation, has secured $340 million in new funding, effectively doubling its valuation to $900 million. This latest round represents a significant milestone for the company, which has now raised a cumulative total exceeding $430 million since its inception.
The company was founded in 2021 by Dr. Tom Kelly, a trauma surgeon, and Waleed Mussa. Heidi's core product focuses on automating administrative and clinical tasks that consume substantial physician time, including clinical note generation, documentation, and evidence research. By leveraging AI agents and workflow automation, the platform aims to reduce the administrative burden on healthcare providers while improving operational efficiency across health systems.
The previous major capital injection came in October 2025, when Heidi closed a $65 million Series B round led by Point72 Private Investments, which valued the company at $465 million at that time. That funding was earmarked to accelerate development of Heidi's AI capabilities and expand its capacity to serve health systems globally. The current $340 million round reflects accelerated investor appetite for the company's solutions and signals confidence in scaling adoption across international markets.
Heidi has achieved recognition as one of Australia's most significant AI success stories, with the founding team comprising doctors, designers, and engineers. The startup's trajectory from Series B to its current valuation in less than a year underscores robust market demand for AI-powered clinical automation solutions and positions Heidi as a notable player in the health-tech venture capital landscape, particularly for institutional investors focused on healthcare innovation and workflow optimization technologies.
The company was founded in 2021 by Dr. Tom Kelly, a trauma surgeon, and Waleed Mussa. Heidi's core product focuses on automating administrative and clinical tasks that consume substantial physician time, including clinical note generation, documentation, and evidence research. By leveraging AI agents and workflow automation, the platform aims to reduce the administrative burden on healthcare providers while improving operational efficiency across health systems.
The previous major capital injection came in October 2025, when Heidi closed a $65 million Series B round led by Point72 Private Investments, which valued the company at $465 million at that time. That funding was earmarked to accelerate development of Heidi's AI capabilities and expand its capacity to serve health systems globally. The current $340 million round reflects accelerated investor appetite for the company's solutions and signals confidence in scaling adoption across international markets.
Heidi has achieved recognition as one of Australia's most significant AI success stories, with the founding team comprising doctors, designers, and engineers. The startup's trajectory from Series B to its current valuation in less than a year underscores robust market demand for AI-powered clinical automation solutions and positions Heidi as a notable player in the health-tech venture capital landscape, particularly for institutional investors focused on healthcare innovation and workflow optimization technologies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.